$392 Million is the total value of GREAT POINT PARTNERS LLC's 35 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 79.2% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SGYPQ | Sell | SYNERGY PHARMACEUTICALS INC CMN | $35,386,000 | +22.7% | 6,422,232 | -15.4% | 9.02% | +9.3% |
DERM | Sell | DERMIRA INC CMN | $22,977,000 | -1.8% | 679,403 | -15.1% | 5.86% | -12.6% |
NBIX | Sell | NEUROCRINE BIOSCIENCES INC CMN | $19,956,000 | -6.6% | 394,080 | -16.2% | 5.09% | -16.8% |
SAGE | Sell | SAGE THERAPEUTICS, INC CMN | $12,198,000 | +22.7% | 264,893 | -19.7% | 3.11% | +9.3% |
TTPH | Sell | TETRAPHASE PHARMACEUTICALS INC CMN | $1,733,000 | -82.5% | 452,375 | -80.3% | 0.44% | -84.4% |
AMRN | Exit | AMARIN CORP PLCspon adr new | $0 | – | -2,000 | -100.0% | -0.00% | – |
RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.03% | – |
RVNC | Exit | REVANCE THERAPEUTICS INC | $0 | – | -21,665 | -100.0% | -0.08% | – |
AXGT | Exit | AXOVANT SCIENCES LTD | $0 | – | -25,000 | -100.0% | -0.09% | – |
PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -29,266 | -100.0% | -0.12% | – |
VCEL | Exit | VERICEL CORP | $0 | – | -253,502 | -100.0% | -0.16% | – |
CLBS | Exit | CALADRIUS BIOSCIENCES INC | $0 | – | -1,525,244 | -100.0% | -0.26% | – |
ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -76,511 | -100.0% | -0.29% | – |
ADVM | Exit | ADVERUM BIOTECHNOLOGIES INC | $0 | – | -550,116 | -100.0% | -0.50% | – |
ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -100,000 | -100.0% | -1.11% | – |
SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -8,173,937 | -100.0% | -1.28% | – |
SRPT | Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -238,900 | -100.0% | -1.30% | – |
RPTP | Exit | RAPTOR PHARMACEUTICAL CORP | $0 | – | -978,350 | -100.0% | -1.50% | – |
ADHD | Exit | ALCOBRA LTD | $0 | – | -1,414,573 | -100.0% | -1.82% | – |
AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -2,457,144 | -100.0% | -2.06% | – |
XNCR | Exit | XENCOR INC | $0 | – | -450,000 | -100.0% | -2.45% | – |
EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -548,290 | -100.0% | -6.09% | – |
BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -500,000 | -100.0% | -6.20% | – |
EXEL | Exit | EXELIXIS INC | $0 | – | -3,200,000 | -100.0% | -7.16% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
SC 13G | 2024-04-08 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.